Market Place
Sourcing Support
Palatin Announces Exercise of Warrants for $3.4M Proceeds
16 Dec 2024 //
PR NEWSWIRE
Palatin Completes Patient Enroll in Ph 2 Study of PL8177 for Colitis
25 Nov 2024 //
PR NEWSWIRE
Palatin Reports Q1 FY 2025 Financial & Operating Results
14 Nov 2024 //
PR NEWSWIRE
Palatin Presents PL7737 Data for Obesity at ObesityWeek® 2024
04 Nov 2024 //
PR NEWSWIRE
Palatin Completes Enrollment in Bremelanotide Obesity Study
31 Oct 2024 //
PR NEWSWIRE
Palatin Presents Inflammatory Healing Data At Peptide Symposium
24 Oct 2024 //
PR NEWSWIRE
Palatin Presents Data On Selective Melanocortin 4 Receptor Agonists
23 Oct 2024 //
PR NEWSWIRE
Palatin Receives Notice of Non-Compliance from NYSE American
07 Oct 2024 //
PR NEWSWIRE
Palatin Reports Q4 2024 Financial Results and Program Updates
01 Oct 2024 //
PR NEWSWIRE
Palatin to Report Fourth Quarter and Fiscal Year End 2024 Results
26 Sep 2024 //
PR NEWSWIRE
Palatin Updates On Clinical Programs And Strategic Priorities
09 Sep 2024 //
PR NEWSWIRE
FDA Accepts Palatin`s Phase 3 Trials For PL9643 In Dry Eye Disease
28 Aug 2024 //
PR NEWSWIRE
Palatin Doses First Patient In Bremelanotide-Tirzepatide Obesity Trial
23 Aug 2024 //
PR NEWSWIRE
Palatin Announces Exercise of Warrants for $6.1 Million Gross Proceeds
21 Jun 2024 //
PR NEWSWIRE
Palatin Begins Phase 2 Study Of Bremelanotide With PDE5i For ED Treatment
20 Jun 2024 //
PR NEWSWIRE
Palatin Initiates Phase 2 Study Of Bremelanotide For Obesity
12 Jun 2024 //
PR NEWSWIRE
Palatin Reports Q3 FY2024 Financials, Corporate Update
15 May 2024 //
PR NEWSWIRE
Palatin Q3 FY2024 Results, Call On May 15
09 May 2024 //
PR NEWSWIRE
Palatin Hosts KOL Event On Melanocortin Agonists On May 8
30 Apr 2024 //
PR NEWSWIRE
Palatin’s stock plummets 43% as lead asset fails PhIII dry eye primary endpoints
29 Feb 2024 //
ENDPTS
Palatin Reports Second Quarter Fiscal Year 2024 Financial Results
15 Feb 2024 //
PR NEWSWIRE
Palatin to Report Second Quarter Fiscal Year 2024 Results
09 Feb 2024 //
PR NEWSWIRE
Palatin Announces Database Lock for PL9643 MELODY-1 Pivotal Phase 3 Trial
05 Feb 2024 //
PR NEWSWIRE
Palatin completes sale of Vyleesi to Cosette Pharmaceuticals for up to $171 mn
02 Jan 2024 //
INDIAN PHARMA POST
Palatin Completes Sale of Vyleesi® to Cosette Pharma for up to $171 Million
20 Dec 2023 //
PR NEWSWIRE
Palatin Receives Notice of Acceptance of the Listing Standards Compliance Plan
18 Dec 2023 //
PR NEWSWIRE
Palatin Announces Quarter Ended September 30 Vyleesi Product Revenue Results
19 Oct 2023 //
PR NEWSWIRE
Palatin Announces Positive Preclinical Data Showing Synergistic Weight Loss
18 Oct 2023 //
PR NEWSWIRE
Palatin Reports Fourth Quarter and Fiscal Year Ended 2023 Financial Results
28 Sep 2023 //
PR NEWSWIRE
Palatin Completes Enrollment in Phase 3 MELODY-1 Study of PL9643
07 Sep 2023 //
PR NEWSWIRE
Palatin Initiates Clinical Program for Bremelanotide Co-Formulated with a PDE5i
10 Aug 2023 //
PR NEWSWIRE
Palatin Announces Direct-to-Consumer Telehealth Partnership with UpScriptHealth
07 Aug 2023 //
PR NEWSWIRE
Palatin to Participate in Canaccord Genuity`s 43rd Annual Growth Conference
04 Aug 2023 //
PR NEWSWIRE
Palatin Announces Preliminary Q4 Fiscal 2023 Vyleesi® Product Revenue Results
11 Jul 2023 //
PR NEWSWIRE
Palatin Presents Preclinical Diabetic Nephropathy Data at Podocyte Conference
30 May 2023 //
PR NEWSWIRE
Palatin Reports Third Quarter Fiscal Year 2023 FYR and Provides Update
16 May 2023 //
PR NEWSWIRE
Palatin Presents PL8177 Ulcerative Colitis Data at Digestive Disease Conference
09 May 2023 //
PR NEWSWIRE
Palatin Invites Investors to Listen to Replay of the PL9643 Dry Eye Disease
08 May 2023 //
PR NEWSWIRE
Palatin Technologies to Host Key Opinion Leader Webinar
01 May 2023 //
PR NEWSWIRE
Palatin reports results of dry eye disease therapy trials
28 Apr 2023 //
CLINICAL TRIALS ARENA
Palatin Presents Data at the Association of Research in Vision & Opht 2023
25 Apr 2023 //
PR NEWSWIRE
Pre-Clinical Data of Palatin`s Melanocortin Agonist Demons Therapeutic Effects
18 Apr 2023 //
PR NEWSWIRE
Frontiers in Immunology Publishes Study of Palatin`s Oral Formulation of PL8177
02 Mar 2023 //
PR NEWSWIRE
Palatin Issued Patent on Vyleesi For Hypoactive Sexual Desire Disorder
28 Feb 2023 //
PR NEWSWIRE
Palatin Reports Second Quarter Fiscal Year 2023 Financial Results
15 Feb 2023 //
PR NEWSWIRE
Palatin to Report Second Quarter Fiscal Year 2023 Results
10 Feb 2023 //
PR NEWSWIRE
Palatin Initiates Enrollment in PII Bremelanotide BREAKOUT Study
19 Jan 2023 //
PR NEWSWIRE
Palatin Receives $4.7 Million of Non-Dilutive Funding
18 Jan 2023 //
PR NEWSWIRE
Frontiers in Immunology Publishes Study of Palatin`s PL8177
10 Jan 2023 //
PR NEWSWIRE
Palatin Announces Preliminary Second Quarter Fiscal 2023 Vyleesi
05 Jan 2023 //
PR NEWSWIRE
Palatin Reports First Quarter Fiscal Year 2023 Financial Results
14 Nov 2022 //
PRNEWSWIRE
Palatin to Report First Quarter Fiscal Year 2023 ResultsTeleconference & Webcast
09 Nov 2022 //
PRNEWSWIRE
Palatin Announces $10 Million Registered Direct Offering
31 Oct 2022 //
PRNEWSWIRE
Palatin Presents PL8177 Data at Annual Meeting
24 Oct 2022 //
PRNEWSWIRE
First Patient Enrolled in Palatin`s PII study of PL8177
20 Oct 2022 //
PRNEWSWIRE
Palatin Announces Publication of Vyleesi fMRI Study in Women with HSDD
17 Oct 2022 //
PRNEWSWIRE
Palatin Announces First Quarter Fiscal 2023 Vyleesi® Product Sales Results
13 Oct 2022 //
PRNEWSWIRE
Palatin Reports Fourth Quarter and Fiscal Year 2022 Financial Results
22 Sep 2022 //
PRNEWSWIRE
Palatin to Report Fourth Quarter and Fiscal Year End 2022 Results
19 Sep 2022 //
PRNEWSWIRE
Palatin Initiated Patient Recruitment for Phase 2 Study Evaluating Oral PL8177
08 Sep 2022 //
PRNEWSWIRE
